Daiichi turns to Nosis for AI-designed RNA delivery tech

Daiichi Sankyo Partners with Nosis Biosciences for AI-Driven RNA Therapeutics

Daiichi Sankyo has entered into a Research Collaboration and Option Agreement with Nosis Biosciences1.
The collaboration aims to develop cell-targeted RNA therapeutics for extrahepatic cell types1.
Nosis' proprietary Connexa™ platform will be leveraged in this partnership1.

Key Details:

Nosis Biosciences' Technology

Nosis Biosciences is an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types1. Their Connexa™ platform represents a breakthrough in RNA medicine by:

Offering the ability to silence any gene in any cell type throughout the body1.
Expanding the reach of RNA-based therapies beyond the liver to critical organs such as the heart, brain, lungs, kidneys, and muscles1.
Integrating AI-powered drug design, single-cell receptor biology, and high-throughput chemistry1.
Mapping over 2,900 receptor targets across 532 cell types for precise delivery1.

Collaboration Details

The partnership between Daiichi Sankyo and Nosis Biosciences aims to:

Leverage Nosis' Connexa™ platform to enable therapeutic access to extrahepatic cell types1.
Develop RNA-based therapies for chronic diseases affecting multiple vital organs1.
Overcome delivery challenges that have limited the potential of RNA therapeutics1.

Significance of the Partnership

This collaboration represents a significant step in the field of RNA therapeutics:

It addresses the limitation of current RNA therapies, which are primarily focused on liver-targeted treatments1.
The partnership could potentially transform patient outcomes by enabling precision treatments for a wider range of diseases1.
It demonstrates the growing interest in expanding the reach of RNA-based medicines beyond the liver4.

Nosis Biosciences' Approach

Nosis' approach to RNA therapeutics involves:

Developing an atlas of almost 3,000 receptors across more than 500 cell types4.
Using AI to design small proteins that can latch onto specific receptors and deliver siRNA drugs to target cells4.
Focusing on inflammatory pathways in chronic diseases that create opportunities for new delivery routes4.

This partnership between Daiichi Sankyo and Nosis Biosciences represents a promising advancement in the field of RNA therapeutics, potentially opening up new avenues for treating a wide range of chronic diseases.

Sources:

1. https://www.nosisbio.com/news/nosis-biosciences-announces-research-collaboration-and-option-agreement-with-daiichi-sankyo-to-develop-cell-targeted-rna-medicines

4. https://bakarlabs.berkeley.edu/daiichi-sankyo-johnson-johnson-partner-with-rna-delivery-startup-nosis-bio/